Evidence map›Paper›PMID 31678298›Full record

ArticleThe journal of allergy and clinical immunology. In practice2020

Safety of cephalosporins in penicillin class severe delayed hypersensitivity reactions.

Jason A Trubiano, Kyra Y L Chua, Natasha E Holmes, Abby P Douglas, Effie Mouhtouris, Michelle Goh, Elizabeth J Phillips

Abstract read
In one paragraph

Article in The journal of allergy and clinical immunology. In practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Non-IgE-Mediated Drug Hypersensitivity Reactions.Current allergy and asthma reports · 2021
    Review
  9. Review
  10. Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?The journal of allergy and clinical immunology. In practice · 2020
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jason A TrubianoInfectious Diseases Department and Centre for Antibiotic Allergy and Research, Austin Health, Heidelberg, VIC, Australia; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, VIC, Australia; Department of Medicine, Austin Health, University of Melbourne, Parkville, VIC, Australia. Electronic address: jason.trubiano@austin.org.au.
Kyra Y L ChuaInfectious Diseases Department and Centre for Antibiotic Allergy and Research, Austin Health, Heidelberg, VIC, Australia.
Natasha E HolmesInfectious Diseases Department and Centre for Antibiotic Allergy and Research, Austin Health, Heidelberg, VIC, Australia.
Abby P DouglasNational Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, VIC, Australia.
Effie MouhtourisInfectious Diseases Department and Centre for Antibiotic Allergy and Research, Austin Health, Heidelberg, VIC, Australia.
Michelle GohDepartment of Dermatology, Austin Health, Heidelberg, VIC, Australia.
Elizabeth J PhillipsInstitute for Immunology and Infectious Diseases, Murdoch University, Murdoch, WA, Australia; Department of Infectious Diseases, Vanderbilt University, Nashville, Tenn. Electronic address: Elizabeth.j.phillips@vanderbilt.edu.
Austin Health · AUPeter MacCallum Cancer Centre · AUMurdoch University · AU

Funding

Understanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DENNY, JOSHUA C. · 2015 to 2019
$13.0M
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivorsR01HG010863 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2019 to 2022
$3.1M
Single Cell definition of pathogenic T cells in Drug-induced Stevens-Johnson-Syndrome/Toxic epidermal necrolysisR21AI139021 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2018 to 2019
$435k
NATIENS: A Phase III Randomized Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisR34AI136815 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2018 to 2018
$205k
NHGRI NIH HHS R01 HG010863NIAID NIH HHS R21 AI139021NIAID NIH HHS R34 AI136815NIGMS NIH HHS P50 GM115305
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug HypersensitivityHypersensitivity, DelayedAnti-Bacterial AgentsCephalosporinsCross ReactionsHumansPenicillinsSkin TestsAnti-Bacterial AgentsCephalosporinsPenicillins

Identifiers

PMID31678298
PMCPMC7064395
OpenAlexW2987963692

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.